Therapeutics News and Research

RSS

Wyeth Pharmaceuticals to acquire Haptogen

Wyeth Pharmaceuticals, a division of Wyeth has announced the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies.

8 Oct 2007

Fraunhofer pharmaceutical agent speeds drug development

It takes a great deal of time and money to develop a new drug. At Biotechnica in Hanover from October 9 to 11, the Fraunhofer Life Sciences Alliance will demonstrate how a pharmaceutical agent can make its way more quickly from the research laboratory to the pharmacy.

8 Oct 2007

Gates Foundation leads the charge against tuberculosis with Northeastern University

Northeastern University announced that Dr. Kim Lewis, Professor of Biology and Director of the Antimicrobial Center, is among the recipients of $280 million in grants the Bill & Melinda Gates Foundation has dedicated to help support the research and speed the development of TB vaccines, diagnostic tests, and treatments.

4 Oct 2007

Isis Pharmaceuticals awarded $1.5 million NIH grant to improve RNAi-based therapeutics

Isis Pharmaceuticals, Inc. has announced that it has been awarded a multi-year Phase 2 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) for up to $1.5 million to design oligonucleotide drugs that can exploit the RNA interference (RNAi) antisense mechanism for disease treatment.

4 Oct 2007

Bath emollients for allergic eczema of 'questionable' value

Specialised bath products to relieve the symptoms of allergic (atopic) eczema are of “questionable” value, says the Drug and Therapeutics Bulletin (DTB).

3 Oct 2007

Daisy compound used to attack cancer stem cells

A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.

2 Oct 2007

Factor MIF a potential target for West Nile virus

Infection with West Nile Virus (WNV) can cause lethal encephalitis and there are currently no vaccines or specific therapeutics for use in humans.

2 Oct 2007

FDA approves Lamisil for child treatment of scalp ringworm

The U.S. Food and Drug Administration announced the approval of Lamisil Oral Granules for the treatment of tinea capitis, a fungal infection of the scalp, in children ages 4 years and older.

29 Sep 2007

Unmasked enzyme may lead to new drugs for type II diabetes

Scientists at the Medical Research Council have made a discovery that could pave the way for better treatments of type II diabetes.

27 Sep 2007

Dietary fatty acids may help prevent diabetes

Omega-3 fatty acids have long been touted for their heart-healthy and brain-boosting benefits. Consider cod liver oil, fortified infant formula and enriched eggs.

27 Sep 2007

Discovery supports theory of Alzheimer's disease as form of diabetes

Insulin, it turns out, may be as important for the mind as it is for the body.

27 Sep 2007

Breast cancer death rate continues to drop

A report from the American Cancer Society finds the breast cancer death rate in the United States continues to drop more than two percent per year, a trend that began in 1990 and is credited to progress in early detection and treatment.

25 Sep 2007

FDA fast tracks PI-88 for the treatment of post resection liver cancer

Progen Pharmaceuticals Limited has announced that its investigational anti-cancer drug PI-88 has been awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

25 Sep 2007

Space flight makes bacteria more infectious

Space flight has been shown to have a profound impact on human physiology as the body adapts to zero gravity environments.

25 Sep 2007

Potential new treatment approach for schizophrenia

A new study reports important evidence for a potential new treatment approach for those diagnosed with schizophrenia.

25 Sep 2007

Adnexus Therapeutics to become a subsidiary of Bristol-Myers Squibb

Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.

25 Sep 2007